28-Oct-2026 08:18:13
JUBILANT INGREVIA Q2 CONCALL : EBITDA SURGES 51% YOY, PAT JUMPS 61%; COMPANY ANNOUNCES ₹189 CR ZETTAONE INVESTMENT & EXPANDS CDMO PIPELINE
• MANAGEMENT EXPECTS GROWTH ACROSS ALL THREE BUSINESS SEGMENTS IN FY27, SUPPORTED BY SPECIALTY CHEMICALS, CDMO, NUTRITION & RECOVERY IN CHEMICAL INTERMEDIATES • MANAGEMENT EXPECTS NEW MULTI-PURPOSE MANUFACTURING PLANT TO BE COMMISSIONED BY FY27-END, SUPPORTING ADDITIONAL FINE CHEMICALS & CDMO CAPACITY • MANAGEMENT HIGHLIGHTS EXPANDING SEMICONDUCTOR CHEMICAL OPPORTUNITIES, WITH NEW GREATER NOIDA R&D & CLEAN-ROOM FACILITIES PLANNED TO SUPPORT DEVELOPMENT • COMPANY PROPOSES ₹189.2 CR INVESTMENT FOR 40% STAKE IN ZETTAONE, MARKING STRATEGIC ENTRY INTO ELECTRONICS DEVELOPMENT & MANUFACTURING SERVICES • MANAGEMENT EXPECTS ZETTAONE FY27 REVENUE GROWTH OF 60–70%, WITH MID-TEEN EBITDA MARGINS; ZETTAONE IS ALSO DEVELOPING A NEW MANUFACTURING FACILITY NEAR BENGALURU • Q2 REVENUE GREW 24% YOY & 7% QOQ TO RECORD ₹1,394 CR, SUPPORTED BY HIGHER VOLUMES, IMPROVED REALISATIONS & BETTER PRODUCT MIX • Q2 EBITDA SURGED 51% YOY TO ₹221 CR, WITH EBITDA MARGIN AT APPROXIMATELY 16% & QUARTERLY EBITDA REACHING A THREE-YEAR HIGH • Q2 NET PROFIT JUMPED 61% YOY TO ₹111 CR, WHILE EPS STOOD AT ₹7.1 • H1 FY27 REVENUE GREW 25% YOY TO ₹2,695 CR, EBITDA INCREASED 44% TO ₹431 CR & NET PROFIT ROSE 50% TO ₹217 CR • SPECIALTY CHEMICALS REVENUE GREW 16% YOY TO ₹560 CR, WITH EBITDA AT ₹140 CR & MARGIN AT APPROXIMATELY 25% • FINE CHEMICALS & CDMO GROWTH WAS SUPPORTED BY DIKETENE DERIVATIVES, HIGHER AGRO INNOVATOR VOLUMES & INCREASING PHARMA CUSTOMER TRACTION IN THE US AND EUROPE • MANAGEMENT REPORTED OVER 25 CONFIRMED MOLECULES IN ITS DEVELOPMENT PIPELINE, WITH ADDITIONAL OPPORTUNITIES IN PHARMA CDMO, AGRO CDMO & SEMICONDUCTOR CHEMICALS • NUTRITION & HEALTH SOLUTIONS REVENUE SURGED 50% YOY TO ₹270 CR, WHILE EBITDA JUMPED 87% TO ₹39 CR, SUPPORTED BY VITAMIN B3 & HIGHER-VALUE PRODUCTS • CHEMICAL INTERMEDIATES REVENUE GREW 24% YOY TO ₹563 CR, WHILE EBITDA SURGED 226% TO ₹64 CR & MARGIN IMPROVED TO APPROXIMATELY 11% FROM 4% • MANAGEMENT REMAINS POSITIVE ON CDMO GROWTH, EUROPEAN ACETIC ANHYDRIDE DEMAND & SEMICONDUCTOR DIVERSIFICATION, BUT INPUT COST INFLATION, CHINESE COMPETITION, SOFT PRODUCT PRICING & ZETTAONE EXECUTION REMAIN KEY RISKS
JUBILANT INGREVIA LIMITED